News Snapshot:
BEIJING-BASED Global Health Drug Discovery Institute (GHDDI) is expected to start clinical trials for two candidate Covid-19 drugs later this year as fresh outbreaks of the highly transmissible Omicron variant in China made it more urgent to create effective and convenient oral anti-coronavirus treatments. Ding Sheng, director of the GHDDI and dean of the School of Pharmaceutical Sciences at Tsinghua University, told Beijing-backed Global Timesthat his research team was accelerating preparations to produce and apply for clinical trials for one of the drugs, called GDI-4405. According to him, they expect their application to be submitted in the second half of...
